| Company Name: |
Nantong QuanYi Biotechnology Co., Ltd
|
| Tel: |
0513-66337626 18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:VMY-1-103
CAS:1209002-43-6
Purity:98%+ HPLC Package:10mg，100mg，500mg，1g，2g，5g，10g，More
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:VMY-1-103
CAS:1209002-43-6
Purity:0 Package:100mg/RMB 17500;50mg/RMB 13800;25mg/RMB 10600
|
|
| | VMY 1-103 Basic information |
| Product Name: | VMY 1-103 | | Synonyms: | VMY 1-103;2-chloro-N-[2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]ethyl]-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzamide;Benzamide, 2-chloro-N-[2-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]ethyl]-4-[[2-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-9-(1-methylethyl)-9H-purin-6-yl]amino]-;2-chloro-N-{2-[5-(dimethylamino)naphthalene-1-sulfonamido]ethyl}-4-[(2-{[(2R)-1-hydroxy-3-methylbutan-2-yl]amino}-9-(propan-2-yl)-9H-purin-6-yl)amino]benzamide | | CAS: | 1209002-43-6 | | MF: | C34H42ClN9O4S | | MW: | 708.27 | | EINECS: | | | Product Categories: | | | Mol File: | 1209002-43-6.mol |  |
| | VMY 1-103 Chemical Properties |
| density | 1.39±0.1 g/cm3(Predicted) | | pka | 10.91±0.50(Predicted) |
| | VMY 1-103 Usage And Synthesis |
| Description | VMY-1-103 is a potent CDK inhibitor, is also a novel dansylated analog of purvalanol B, was shown to inhibit cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B. VMY-1-103 , but not purvalanol B, significantly decreased the proportion of cells in S phase and increased the proportion of cells in G(2)/M. VMY-1-103 increased the sub G(1) fraction of apoptotic cells, induced PARP and caspase-3 cleavage and increased the levels of the Death Receptors DR4 and DR5, Bax and Bad while decreasing the number of viable cells, all supporting apoptosis as a mechanism of cell death. VMY-1-103 possesses unique antiproliferative capabilities and that this compound may form the basis of a new candidate drug to treat medulloblastoma. |
| | VMY 1-103 Preparation Products And Raw materials |
|